Table 1.

Breadth and potency of antibodies that may be used in clinical trials on an 80 virus panel organized by subtype as generated by CATNAP http://hiv.lanl.gov/catnap [28]

		10-1074	10E8	3BNC117	PGDM 1400	PGT121	VRC01	VRC07-523-LS	VRC 26.25
Subtype AE(n = 9)	% Virus Neutralized (IC80 < 10 μg/ml)	0	100	89	89	0	89	89	67
	Geometric Mean(IC80 < 10 μg/ml)	n/a	1.75	0.326	0.021	n/a	1.09	0.269	0.055
Subtype AG(n = 6)	% Virus Neutralized(IC80 < 10 μg/ml)	83	100	83	67	50	67	83	67
	Geometric Mean(IC80 < 10 μg/ml)	0.536	1.37	0.251	0.035	0.511	0.677	0.169	0.087
Subtype A1(n = 13)	% Virus Neutralized(IC80 < 10 μg/ml)	38	77	85	85	46	85	85	62
	Geometric Mean(IC80 < 10 μg/ml)	0.143	4.60	0.085	0.034	0.140	0.266	0.073	0.091
Subtype B(n = 15)	%Virus Neutralized(IC80 < 10 μg/ml)	87	100	87	67	80	93	100	13
	Geometric Mean(IC80 < 10 μg/ml)	0.154	2.22	0.260	0.449	0.236	0.941	0.234	0.538
Subtype C(n = 37)	% Virus Neutralized(IC80 < 10 μg/ml)	62	89	70	70	59	86	95	65
	Geometric Mean(IC80 < 10 μg/ml)	0.226	1.65	0.402	0.030	0.163	1.00	0.184	0.010

n/a not applicable